Given the aggressive coagulopathy associated with APL (85% of cases) [7], it is imperative that cryptic PML::RARA translocations are identified early to initiate ATRA/ATO given the resistance of APL to standard induction chemotherapy regimens. This evidence concerns the gene PML and acute promyelocytic leukemia.